Get started
Author

Mengxing You

Prognostic value of fatty acid metabolism-related genes in patients with hepatocellular carcinoma
2021 · Dongsheng He, Lifang Cai, et al. · Aging · 37
PDF
Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma
2021 · Dongsheng He, Shengyin Liao, et al. · BMC Cancer · 9
PDF
Prognostic Value of a Ferroptosis-Related Gene Signature in Patients With Head and Neck Squamous Cell Carcinoma
2021 · Dongsheng He, Shengyin Liao, et al. · Frontiers in Cell and Developmental Biology · 8
PDF
Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion
2022 · Xuehua Xie, Mengxing You, et al. · Journal of Cancer Research and Clinical Oncology · 6
PDF
First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes
2025 · Mengxing You, Lige Wu, et al. · Thoracic Cancer · 2
PDF
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer
2025 · Mengxing You, Jiayu Liu, et al. · Translational Lung Cancer Research · 2
The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy
2023 · Zhiyang Xu, Hongqian Ke, et al. · Cancer Control · 2
PDF
[Analysis of risk factors for spontaneous rupture of hepatocellular carcinoma].
2013 · Meng-xing You, Xi-xiang Yu, et al. · PubMed · 2
Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma
2026 · Tongji Xie, Lige Wu, et al. · Signal Transduction and Targeted Therapy · 1
PDF
Development of a prognostic nomogram for ocular melanoma: a SEER population-based study (2000–2021)
2025 · Miyun Zheng, Maodong Xu, et al. · Frontiers in Medicine · 1
PDF
Development of a prognostic nomogram and risk stratification system for upper thoracic esophageal squamous cell carcinoma
2023 · Yu Lin, Binglin Zheng, et al. · Frontiers in Oncology · 1
Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights
2026 · Mengxing You, Tongji Xie, et al. · Neuro-Oncology
High-dose furmonertinib in EGFR -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.
2026 · Mengxing You, Puyuan Xing, et al. · Journal of Clinical Oncology
Author response for "The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy"
2023 · Zhiyang Xu, Hongqian Ke, et al. · Publons reviews and discussion
The prognostic significance of nomogram-based pretreatment inflammatory indicators in patients with esophageal squamous cell carcinoma receiving intensity- modulated radiotherapy
2022 · Zhiyang Xu, Hongqian Ke, et al. · Research Square
The prognostic significance of nomogram-based pretreatment inflammatory indicators in patients with esophageal squamous cell carcinoma receiving intensity- modulated radiotherapy
2022 · Zhiyang Xu, Hongqian Ke, et al. · Research Square
PDF
Development of a prognostic nomogram and risk stratification system for upper thoracic esophageal squamous cell carcinoma
2022 · Yu Lin, Binglin Zheng, et al. · Research Square
Development of a Prognostic Nomogram and Risk Stratification System for Upper Thoracic Esophageal Squamous Cell Carcinoma
2021 · Yu Lin, Binglin Zheng, et al. · Research Square
PDF
Works count: 18
Citation count: 71
H-index: 4
I10-index: 1
Year
Topic
Type